RIEMSER Pharma GmbH Ready for the Future

Transcription

1 RIEMSER Pharma GmbH Ready for the Future Jefferies Health Care Conference 19 th & 20 th November 2014 The Waldorf Hilton, London Präsentationstitel von Dr. Vorname Nachname 1

2 Fast international market access Strong marketing capabilities Excellence in Marketing and Sales Well-established international partner network Strong Market Access and Regulatory experience Highly efficient BD team 2

3 Corporate Structure Kai Deusch, M.D. PhD Chief Executive Officer Advisory Board Elmar Stachels PhD (formerly Bayer) Thomas Werner PhD (formerly MD GSK, BMS- Germany) Burkhart Blank MD (formerly Boehringer I) Beatrice von Buchwaldt Chief Financial Officer RIEMSER supervisory board since Sept. 2012, CEO since Feb Senior positions in Clinical Academia (Harvard DFCI, University Munich) Consulting: McKinsey & Company Private Equity: Director, Apax Partners, Medicis Various pharma & medtech companies With RIEMSER since April 2011 Previously worked for MARS, BRITA Waterfilters, Teraklin and Vaillant Christophe Pasik Managing Director Keocyt (formerly Pfizer France) EU5-Country Managing Director EU5-Country Managing Director 3

4 Dynamic Development Acquisition by Ardian Private Equity Strategic Metamorphosis Diversified Pharma / Device / OTC Company Merger of RIEMSER Tierarzneimittel (animal health) with Palmicol into RIEMSER Arzneimittel GmbH Acquisition of dental business and 400+ marketing authorisations Consolidation & Strategic Growth Strategic focus on oncology, antiinfectives and dermatology Targeted acquisitions and developments (Aloxi, Ostac,Tepadina) and divestments (animal health) Initiation of internationalization Divestment of RIEMSER s nonstrategic business: o Dental ORM /OIM o Manufacturing sites o Reduction of portfolio by 50% to approx. 50 products Geographic (EU) Footprinting & Strategic Portfolio Expansion o Acquisition of Keocyt in France (04/2014) with 2 Oncology and 2 Neurology products + pipeline o Acquisition plans in Italy, Spain and UK o Strategic product/portfolio acquisitions Phase Phase Phase to date 4

5 Continuous Growth Sales close to 110m in 2014 CAGR (%) 39% 38% 9.2% 32% 29% 32% 13.9% 71% 68% 61% 62% 68% 6.7% National International 5

6 Core Competencies Re-launch and repositioning of existing products Launch of innovative niche products and orphan drugs Others 25% (e.g. Immunology/ Obesity) Anti-infectives 22% Acquisition and integration capabilities Licensing of strategic products Dermatology 8% Cardiovascular 15% Oncology 30% Global distribution network 6

7 Key Therapeutic Areas Oncology Neurology Anti-Infectives Cardiovascular Dermatology Tepadina Aloxi Ostac Gelclair Dilantin Prodilantin Vancomycin Enterocaps Eremfat Lanitop Ismo Aldactone Vagantin Bite-away Herpotherm Zanosar Estracyt Akynzeo* Dedicated sales force in Germany and France Dedicated sales force in France KOL network Direct Marketing KOL network Direct Marketing KOL network Direct Marketing *pre-approval phase 7

8 RIEMSER Can Make a Difference (1) Aloxi 5-HT3 receptor antagonist for prevention of CTinduced nausea and vomiting Launched in 2005 In-licensed from Helsinn in 2008 after flattened sales development by previous licensee Re-positioning as best-inclass setron Retail Sales ( ) 8,000,000 7,000,000 6,000,000 5,000,000 4,000,000 3,000,000 2,000,000 1,000, %* +484% *First full year with RIEMSER versus last full year with previous licensee

9 RIEMSER Can Make a Difference (2) Tepadina Sales ( ) 10,000,000 9,000, % For conditioning treatment prior to HSCT Developed in a global partnership with Adienne New MA granted in 3/2010 New positioning with orphan drug status at an attractive price Expansion into new indications and markets (France, selected Eastern European countries, Asia) 8,000,000 7,000,000 6,000,000 5,000,000 4,000,000 3,000,000 2,000,000 1,000, %* *First year after repositioning versus previous year

10 RIEMSER Can Make a Difference (3) Bite-away Sales ( ) 1,800,000 1,600, %* Electrical device to treat insect bites Initiation of direct-to-customer promotion in 2013 Usage by celebrities Distribution through Amazon etc. Line extension for the treatment of herpes labialis 1,400,000 1,200,000 1,000, , , , , *First year after start of DTC promotion versus previous year 10

11 Mission & Strategy Mission Establish a leading European specialty pharma player Strategy Focus on therapeutics and supportive care products around selected complex disease areas o o o Marketing & distribution excellence in complex disease areas Efficient BD transaction team Proprietary deal flow through unique network Employ/grow expert market access & distribution know how Establish solid footprint in key European regions through targeted acquisitions o Ideal partner for innovative companies to launch specialty products in Europe 11

12 Becoming an European Specialty Pharma Player Transition towards a fully integrated European company Riemser Europe Riemser France 12

13 Worldwide Distribution Network with Trusted Partners SP = specialty pharma products, EP= established pharma products 13

14 Key Priorities for the Future Focus on Key Therapeutic Areas Continue Acquisition and Licensing Strategy Expand European Footprint Build on existing expertise in Oncology, Dermatology, Anti-infectives and Cardiovascular Use existing competencies to tap into Autoimmune diseases, Immunology, Neurology and Transplantation Experienced and flexible team Efficient and effective execution Establish affiliates in all Big 5 countries Become an European specialty pharma player with an entrepreneurial spirit Manage and expand current well- functioning partner network 14

15 RIEMSER is your preferred partner for: Company Acquisitions Co-detailing Product Acquisition Copromotion Licensing 15

16 In Summary RIEMSER Pharma Highly focused specialty pharma company ideally suited to serve as partner for innovative pharma companies targeting disease areas with high unmet medical need Rich global pipelines in oncology, immunology and other complex/niche chronic diseases require highly specialized partners such as RIEMSER Rise of personalized medicine requires more refined sales strategies than in the past RIEMSER is perfectly positioned to market innovative, non-mainstream therapeutics in oncology, autoimmunity, neurology and other specialty niches 16

17 THANK YOU 17